Timber Pharmaceuticals receives European ODD for TMB-001

Timber Pharmaceuticals announced the European Commission, EC, granted orphan drug designation, ODD, for TMB-001 for the treatment of X-linked recessive ichthyosis, XRLI, on February 15, 2023. "We are pleased to receive an additional orphan drug designation in Europe for the treatment of XLRI as we continue to make steady progress with our global Phase 3 clinical trial," said John Koconis, Chairman and Chief Executive Officer of Timber. "These orphan drug designations underscore the significant unmet needs in congenital ichthyosis, which can lead to a limited range of motion, chronic itching, an inability to sweat normally, high risk of secondary infections, and impaired eyesight or hearing. We believe the targeted delivery of therapies to the epidermis and dermis may be able to minimize systemic absorption and we are committed to bringing a potential new treatment option to this rare disease community."